Skip to main content
. 2023 Jan 31;7(10):2008–2017. doi: 10.1182/bloodadvances.2022009389

Figure 2.

Figure 2.

EFS and OS in patients with high BCL2/MYC coexpression by treatment arm. Overall EFS (A) and OS (B) in patients with high BCL2/MYC coexpression by RNA-seq in the placebo plus R-CHOP and ibrutinib plus R-CHOP arms.